US Companion Diagnostic Markets 2021-2025 - CDs are Poised to Revolutionize the Diagnostics Industry
Dublin, Oct. 12, 2021 (GLOBE NEWSWIRE) -- The "Companion Diagnostic Markets 2021-2025" report has been added to ResearchAndMarkets.com's offering.
This report provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help understand test pricing in detail.
Forecast demand for new testing regimes or technologies. Make research investment decisions. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth.
Companion Diagnostics are poised to revolutionize the diagnostics industry. The market is finally moving out of the lab and into the clinic. Oncology, especially immune-oncology is leading the way. And the FDA is holding the door open for this diagnostic technology of the future. But COVID-19 is impacting healthcare treatment everywhere and lowering demand for specialized cancer testing. Find out the latest outlook for this important market.
Learn all about how diagnostic players are jockeying for position with their pharmaceutical counterparts and creating new and significant business opportunities.
And some players are already taking the lead. It is a dynamic market situation with enormous opportunity. Diagnostic companies are trying to back the right horse. The science is racing forward. And the cost of molecular diagnostics continues to fall.
Market Trends
Factors Driving Growth
Level of Care
Immuno-oncology
Liability
Aging Population
Factors Limiting Growth
State of knowledge
Genetic Blizzard
Protocol Resistance
Regulation and coverage
Instrumentation and Automation
Instruments Key to Market Share
Bioinformatics Plays a Role
Diagnostic Technology Development
Next Generation Sequencing Fuels a Revolution
Single Cell Genomics Changes the Picture
Pharmacogenomics Blurs Diagnosis and Treatment
CGES Testing, A Brave New World
Biochips/Giant magneto resistance based assay
Companion Diagnostics Recent Developments
HTG Molecular Diagnostics 2020 Revenues Fall 56%
Oncocyte Details Expansions Plans
Agilent Acquires Resolution Biosciences
Qiagen, Inovio Expand CDx Partnership
AmoyDx, AstraZeneca Strike Ovarian Cancer CDx Alliance
NeoGenomics to Grow Through CDx Agreements, Acquisitions
Personalis Neoantigen Platform Driving Improved Immunotherapy Prediction
Biocartis Collaborating with Endpoint Health on CDx Tests for Idylla Platform
FDA Approves Foundation Medicine Test as CDx for Three Targeted Therapies
Promega to Develop MSI Assay as CDx
HTG Molecular Q2 Revenues Drop 66 Percent
Guardant Health to Develop CDx for Janssen
Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx .
FDA Approval for FoundationOneCDx
FDA finalizes CDx Guidance
QIAGEN Launches CDx Therascreen BRAF Test
Myriad Genetics Seeks Approval for Companion Diagnostic
ARUP Labs Seek PMA for Hemophilia Gene Therapy CDx
QIAGEN Builds on Global Collaboration with Amgen
Foundation Medicine nabs 19th companion Dx
Maze Therapeutics Uses CRISPR for Precision Medicine Companion Diagnostics
Myriad Wins Japanese Approval for BRACAnalysis
Fujitsu Improves Efficiency in Cancer Genomic Medicine
Thermo Fisher's automated sequencer to offer same-day, pan-cancer test results
Takeda, Prometheus Enter IBD Drug-Companion Diagnostic Partnership
Thermo Fisher, Eli Lilly Ink CDx Collaboration in NSCLC, Thyroid Cancer
Roche VENTANA PD-L1 (SP142) Assay approved as companion diagnostic
Universal Genetic Testing for All Breast Cancer Patients
Exact Sciences buys Genomic Health
Biodesix Highlights Pipeline and Companion Diagnostic Development
Companies Mentioned
10x Genomics, Inc
Abbott Diagnostics
AccuraGen Inc
Adaptive Biotechnologies
Aethlon Medical
Agena Bioscience, Inc.
Agilent
Anchor Dx
ANGLE plc
ApoCell, Inc.
ArcherDx, Inc
ARUP Laboratories
Asuragen
AVIVA Biosciences
Baylor Miraca Genetics Laboratories
Beckman Coulter Diagnostics
Becton, Dickinson and Company
BGI Genomics Co. Ltd
Bio-Rad Laboratories, Inc
Bio-Reference Laboratories
Bio-Techne
Bioarray Genetics
Biocartis
Biocept, Inc
Biodesix Inc
BioFluidica
BioGenex
BioIVT
Biolidics Ltd
bioMerieux Diagnostics
Bioneer Corporation
Bioview
Bolidics
Boreal Genomics
Bristol-Myers Squibb
Cancer Genetics
Caris Molecular Diagnostics
Castle Biosciences, Inc.
CellMax Life
Cepheid (now Danaher)
Charles River Laboratories
Chronix Biomedical
Circulogene
Clinical Genomics
Cynvenio
Cytolumina Technologies Corp
CytoTrack
Datar Cancer Genetics Limited
Diagnologix LLC
Diasorin S.p.A
Enzo Life Sciences, Inc
Epic Sciences
Epigenomics AG
Eurofins Scientific
Exosome Diagnostics
Exosome Sciences
Fabric Genomics
Fluidigm Corp
Fluxion Biosciences
Foundation Medicine
Freenome
GeneFirst Ltd.
Genetron Health (Beijing) Co., Ltd.
Genomic Health
GenomOncology
GILUPI Nanomedizin
Grail, Inc.
Guardant Health
HalioDx
HansaBiomed
HeiScreen
Helomics
Horizon Discovery
HTG Molecular Diagnostics
iCellate
Illumina
Incell Dx
Inivata
Integrated Diagnostics
Invivogen
Invivoscribe
Janssen Diagnostics
MDNA Life SCIENCES, Inc
MDx Health
Menarini Silicon Biosystems
Millipore Sigma
Miltenyi Biotec
MIODx
miR Scientific
Molecular MD
MyCartis
Myriad Genetics/Myriad RBM
NantHealth, Inc.
Natera
NeoGenomics
New Oncology
Novogene Bioinformatics Technology Co., Ltd.
Oncocyte
OncoDNA
Ortho Clinical Diagnostics
Oxford Nanopore Technologies
Panagene2
Perkin Elmer
Personal Genome Diagnostics
Personalis
Precipio
PrecisionMed
Promega
Qiagen Gmbh
Rarecells SAS
RareCyte
Roche Molecular Diagnostics
Screencell
Sense Biodetection.
Serametrix
Siemens Healthineers
Silicon Biosystems
simfo GmbH
Singlera Genomics Inc
Singulomics
SkylineDx
Stratos Genomics
Sysmex Inostics
Tempus Labs, Inc
Thermo Fisher Scientific Inc
Thrive Earlier Detection
Todos Medical
Trovagene
Volition
Vortex Biosciences
For more information about this report visit https://www.researchandmarkets.com/r/vord04
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900